Actively Recruiting
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2025-12-05
220
Participants Needed
2
Research Sites
144 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective study will compare pre-post pilot test of surgeon-facing, visual decision support among urologists seeing patients with newly diagnosed localized prostate and kidney cancer. Up to 20 urologists (10 academic and 10 community) will be enrolled. The goal will be to capture up to 10 pre- and 10 post-intervention patient encounters for each urologist with an accrual target of 200 unique patient visits (100 pre and 100 post-intervention) over a half-year period. Patient encounters pre- and post-intervention will be audio recorded, transcribed, and coded for discussion of risks/benefits of surgery and strength of recommendation. Patients and urologists will complete additional surveys on their perceptions of patient-provider communication. Urologists will further describe their experience and rate their satisfaction with visual decision support. Communication (content and perceived) will be compared pre- and post-intervention with secondary comparisons by race and care setting. It was hypothesized that the discussion of risks and benefits of cancer surgery will increase post-intervention and that the strength of recommendation and perceptions of patient-provider communication will change. The secondary hypothesis is that these changes will differ by patient race and care setting.
CONDITIONS
Official Title
Designing Visual Tools to Enhance Cancer Surgeon Decision-making
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Verbal informed consent was obtained to participate in the study.
- Subject is willing and able to comply with study procedures based on investigator judgment.
- Age 18 years or older at the time of consent.
- For patients: new histologic diagnosis of localized prostate cancer based on biopsy or clinical diagnosis of T1 renal mass (7 cm or smaller) suspicious for kidney cancer within 6 months of consent.
- For physicians: practicing urologist in North Carolina at UNC Health, Novant Health, or affiliated sites who sees patients with suspected or confirmed prostate or kidney cancer.
You will not qualify if you...
- Non-English speaking.
- Unwilling or unable to complete informed consent.
- For patients: staging indicating locally advanced or metastatic disease, including PSA over 50 ng/ml, imaging showing distant metastasis or lymph node involvement, renal masses larger than 7 cm, invasion of renal sinus, or tumor thrombus.
- Histologic or clinical diagnosis more than 6 months before consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
2
New Hanover Regional Medical Center
Wilmington, North Carolina, United States, 28401
Not Yet Recruiting
Research Team
D
Deborah Usinger
CONTACT
T
Taylor Greene
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here